

Securing the Future of Iodinated Contrast Media

Iodinated contrast media is essential to you and your patients, and the recent supply shortage demonstrated just how critical it is. At GE Healthcare, we're investing to build more resiliency into the supply chain and secure the future supply of iodinated contrast for you and your patients.

We estimate that volume demand for contrast media will double in the next ten years.¹ As such, significant investment is needed to close the growing gap between support and demand in order to secure future supply.

From extraction to injection

GE Healthcare is investing, from extraction to injection, to secure future iodinated contrast media supply.² This approach is built upon four main pillars:

GE Healthcare has invested almost \$400M in the past several years to increase production capacity, and continue to invest to secure the long-term supply of contrast media.²

Extraction • • •



Extraction and processing of iodine: We're securing and protecting long-term supply



Production of API: Lindesnes, Norway— We're producing more API for more contrast media



Fill and finish: Cork, Oslo, Shanghai — We're producing ~30% more patient doses by 2025¹



Injection

Patient dose: We're enabling personalized dosing, reduced waste, and more efficient workflows











We're securing and protecting long-term iodine supply

- · lodine is a limited, nonrenewable resource, and demand is increasing
- Future contrast media demand requires a growing, reliable supply of iodine
- We're securing long-term agreements to ensure future iodine supply

We're producing more API for more iodinated contrast media

- Our Active Pharmaceutical Ingredient (API) manufacturing site at Lindesnes, Norway, is the largest iodinated contrast media API facility in the world
- We are investing to expand our API capacity by ~30% by 2025¹

We're producing more doses in our secondary manufacturing fill and finish sites

- GE Healthcare currently produces 110 million doses globally
- We are investing to expand capacity at our fill and finish facilities to produce ~30% more patient doses by 2025¹

We're enabling personalized dosing, reduced waste, and improved workflow

- Increasing integration with contrast media injectors
- Producing more iodinated contrast media in larger, multidose +PLUSPAK™ polymer packaging, reducing downtime from breakages and metal ring pull injuries³

Consider GE Healthcare for your supplier of contrast media

We are committed to you, your patients, and their procedures. GE Healthcare provides a broad comprehensive portfolio of contrast media products that help meet your patient and procedural needs across a multitude of modalities.

To learn more, please visit <u>www.gehealthcare.com/products/contrast-media</u> or feel free to contact us directly, <u>here</u>, with specific questions.



References:1. Data on file. GE Healthcare Planned Investment; 2022.2. Data on file. GE Healthcare Investment; 2021.

3. Marshall G. Sharps injuries among radiographers: Dangers associated

with opening bottles of contrast agent. Radiography. 2008;14:128-134.

© GE, 2022 GE and the GE Monogram are trademarks of GE.